The IgM response to modified LDL in experimental atherosclerosis: Hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 274-279

  Van Leeuwen, Marcella ^a   Damoiseaux, Jan ^a,c   Duijvestijn, Adriaan ^a   Heeringa, Peter ^b   Gijbels, Marion ^a   De Winther, Menno ^a   Tervaert, Jan Willem Cohen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; HOCl modified LDL; IgM antibodies; Mouse

Indexed keywords

CHOLESTEROL; HYPOCHLORITE; IMMUNOGLOBULIN M ANTIBODY; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID DIET; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL;

MUS;

EID: 70049101610     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04657.x     Document Type: Conference Paper

References (27)

1. Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
2. Iughetti, L. et al. 1999. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr. Res. 45: 94-99.
3. Tinahones, F.J. et al. 2002. Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism 51: 429-431.
4. Gounopoulos, P. et al. 2007. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 55: 821-837.
5. Palinski, W. et al. 1995. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arte-rioscler. Thromb. Vasc. Biol. 15: 1569-1576.
6. Yla-Herttuala, S. et al. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14: 32-40.
7. Binder, C.J. et al. 2005. Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. J. Lipid Res. 46: 1353-1363.
8. Shoenfeld, Y. et al. 2004. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110: 2552-2558.
9. Huang, Y. et al. 1999. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol 19: 1600-1607.
10. Kiener, P.A. et al. 1995. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 15: 990-999.
11. Chang, M.K. et al. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. USA 96: 6353-6358.
12. Boes, M. 2000. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 37: 1141-1149.
13. Faria-Neto, J.R. et al. 2006. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189: 83-90.
14. Witztum, J.L. & D. Steinberg. 2001. The oxida-tive modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11: 93-102.
15. Podrez, E.A. et al. 1999. Myeloperoxidase-generated reactive nitrogen species convert LDL into an athero-genic form in vitro. J. Clin. Invest. 103: 1547-1560.
16. Stocker, R. & J.F. Keaney, Jr. 2004. Role of oxida-tive modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478.
17. Daugherty, A. et al. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94: 437-444.
18. van Leeuwen, M. et al. 2008. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arterioscler. Thromb. Vasc. Biol. 28: 84-89.
19. Slot, M.C. et al. 2007. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins. Clin. Exp. Immunol. 149: 257-264.
20. Tornvall, P. et al. 2003. Autoantibodies against modified low-density lipoproteins in coronary artery disease. Atherosclerosis 167: 347-353.
21. Binder, C.J. et al. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743.
22. Shaw, P.X. et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
23. Baumgarth, N., J.W. Tung & L.A. Herzenberg. 2005. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26: 347-362.
24. Binder, C.J. et al. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427-437.
25. Lutz H.U. 2007. Homeostatic roles of naturally occurring antibodies: An overview. J. Autoimmun. 29: 287-294.
26. Matsuura, E., G.R. Hughes & M.A. Khamashta. 2008. Oxidation of LDL and its clinical implication. Autoimmun. Rev. 7: 558-566.
27. Nilsson, J. & G.K. Hansson. 2008. Autoimmunity in atherosclerosis: a protective response losing control? J. I n t e r n . M e d . 263: 464-478.